Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

108 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Lisocabtagene maraleucel versus standard of care with salvage chemotherapy followed by autologous stem cell transplantation as second-line treatment in patients with relapsed or refractory large B-cell lymphoma (TRANSFORM): results from an interim analysis of an open-label, randomised, phase 3 trial.
Kamdar M, Solomon SR, Arnason J, Johnston PB, Glass B, Bachanova V, Ibrahimi S, Mielke S, Mutsaers P, Hernandez-Ilizaliturri F, Izutsu K, Morschhauser F, Lunning M, Maloney DG, Crotta A, Montheard S, Previtali A, Stepan L, Ogasawara K, Mack T, Abramson JS; TRANSFORM Investigators. Kamdar M, et al. Among authors: lunning m. Lancet. 2022 Jun 18;399(10343):2294-2308. doi: 10.1016/S0140-6736(22)00662-6. Lancet. 2022. PMID: 35717989 Clinical Trial.
The curability of follicular lymphoma.
Lunning M, Armitage JO. Lunning M, et al. Transfus Apher Sci. 2007 Aug;37(1):31-5. doi: 10.1016/j.transci.2007.04.012. Transfus Apher Sci. 2007. PMID: 17936072 Review.
Intensive induction chemotherapy followed by early high-dose therapy and hematopoietic stem cell transplantation results in improved outcome for patients with hepatosplenic T-cell lymphoma: a single institution experience.
Voss MH, Lunning MA, Maragulia JC, Papadopoulos EB, Goldberg J, Zelenetz AD, Horwitz SM. Voss MH, et al. Among authors: lunning ma. Clin Lymphoma Myeloma Leuk. 2013 Feb;13(1):8-14. doi: 10.1016/j.clml.2012.09.002. Epub 2012 Oct 27. Clin Lymphoma Myeloma Leuk. 2013. PMID: 23107915 Free PMC article.
The potential benefit of allogeneic over autologous transplantation in patients with very early relapsed and refractory follicular lymphoma with prior remission duration of ≤12 months.
Lunning MA, Migliacci JC, Hilden P, Devlin SM, Castro-Malaspina H, Giralt S, Perales MA, Zelenetz AD, Moskowitz CH, Sauter CS. Lunning MA, et al. Br J Haematol. 2016 Apr;173(2):260-4. doi: 10.1111/bjh.13947. Epub 2016 Feb 5. Br J Haematol. 2016. PMID: 26847389 Free PMC article.
Diffuse Large B-Cell Lymphoma Version 1.2016.
Zelenetz AD, Gordon LI, Wierda WG, Abramson JS, Advani RH, Andreadis CB, Bartlett N, Byrd JC, Fayad LE, Fisher RI, Glenn MJ, Habermann TM, Lee Harris N, Hernandez-Ilizaliturri F, Hoppe RT, Horwitz SM, Kaminski MS, Kelsey CR, Kim YH, Krivacic S, LaCasce AS, Lunning M, Nademanee A, Porcu P, Press O, Rabinovitch R, Reddy N, Reid E, Roberts K, Saad AA, Sokol L, Swinnen LJ, Vose JM, Yahalom J, Zafar N, Dwyer M, Sundar H. Zelenetz AD, et al. Among authors: lunning m. J Natl Compr Canc Netw. 2016 Feb;14(2):196-231. doi: 10.6004/jnccn.2016.0023. J Natl Compr Canc Netw. 2016. PMID: 26850490
NCCN Guidelines Insights: Non-Hodgkin's Lymphomas, Version 3.2016.
Horwitz SM, Zelenetz AD, Gordon LI, Wierda WG, Abramson JS, Advani RH, Andreadis CB, Bartlett N, Byrd JC, Fayad LE, Fisher RI, Glenn MJ, Habermann TM, Lee Harris N, Hernandez-Ilizaliturri F, Hoppe RT, Kaminski MS, Kelsey CR, Kim YH, Krivacic S, LaCasce AS, Lunning M, Nademanee A, Press O, Rabinovitch R, Reddy N, Reid E, Roberts K, Saad AA, Sokol L, Swinnen LJ, Vose JM, Yahalom J, Zafar N, Dwyer M, Sundar H, Porcu P. Horwitz SM, et al. Among authors: lunning m. J Natl Compr Canc Netw. 2016 Sep;14(9):1067-79. doi: 10.6004/jnccn.2016.0117. J Natl Compr Canc Netw. 2016. PMID: 27587620
Non-Hodgkin lymphoma.
Armitage JO, Gascoyne RD, Lunning MA, Cavalli F. Armitage JO, et al. Lancet. 2017 Jul 15;390(10091):298-310. doi: 10.1016/S0140-6736(16)32407-2. Epub 2017 Jan 31. Lancet. 2017. PMID: 28153383 Review.
Standard-of-Care Axicabtagene Ciloleucel for Relapsed or Refractory Large B-Cell Lymphoma: Results From the US Lymphoma CAR T Consortium.
Nastoupil LJ, Jain MD, Feng L, Spiegel JY, Ghobadi A, Lin Y, Dahiya S, Lunning M, Lekakis L, Reagan P, Oluwole O, McGuirk J, Deol A, Sehgal AR, Goy A, Hill BT, Vu K, Andreadis C, Munoz J, Westin J, Chavez JC, Cashen A, Bennani NN, Rapoport AP, Vose JM, Miklos DB, Neelapu SS, Locke FL. Nastoupil LJ, et al. Among authors: lunning m. J Clin Oncol. 2020 Sep 20;38(27):3119-3128. doi: 10.1200/JCO.19.02104. Epub 2020 May 13. J Clin Oncol. 2020. PMID: 32401634 Free PMC article.
108 results